Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FibroGen’s Roxadustat Rejected By US FDA Panel Due To Safety Concerns, Untested Dosing Strategy

Executive Summary

But advisory committee members see a potential opportunity for the oral anemia drug in small percentage of dialysis-dependent patients not responsive to erythropoiesis-stimulating agents; FibroGen’s revised dosing algorithm, aimed at slowing hemoglobin rate of increase and reducing risk of thrombosis, needs to be clinically tested before marketing approval, panelists said.

You may also be interested in...



Good News At Last For GSK With Daprodustat, But Safety Scrutiny Awaits

GSK could gain a first-in-class approval for anemia in chronic kidney disease in the US, but approval and uptake of the HIF inhibitor in non-dialysis patients remain uncertain.

FibroGen May Have A New Opening For Roxadustat In The US

The company announced positive Phase II data for roxadustat in chemotherapy-induced anemia.

Ellis Unger’s US FDA Farewell Address?

The US FDA advisory committee review of AstraZeneca/FibroGen’s roxadustat for anemia was the last in the long tenure of Office of Cardiology Director Ellis Unger. His opening remarks struck a valedictory tone.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS144641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel